Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21096055 | 0.89 | ALDH1A1 (0.37) | LMNATDP1ALDH1A1KMT2AHTT | |
| SCHEMBL19494607 | 0.86 | LMNA (0.38) | LMNATDP1ALDH1A1GAAPKM | |
| SCHEMBL21712680 | 0.80 | LMNA (0.39) | LMNATDP1ALDH1A1GAAPKM | |
| SCHEMBL21096327 | 0.73 | HTT (0.42) | LMNATDP1ALDH1A1GAAPKM | |
| SCHEMBL15746150 | 0.73 | KIF11 (0.42) | HSD11B1MAPT | |
| SCHEMBL15746170 | 0.70 | LMNA (0.52) | LMNATDP1ALDH1A1GAAPKM | |
| SCHEMBL29728144 | 0.69 | ESR1 (0.46) | LMNATDP1ALDH1A1GAAKMT2A | |
| SCHEMBL47866 | 0.69 | ESR1 (0.46) | LMNATDP1ALDH1A1GAAKMT2A | |
| SCHEMBL19465208 | 0.68 | DAO (0.35) | — | |
| SCHEMBL13538944 | 0.67 | ESR1 (0.50) | LMNATDP1ALDH1A1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10427997-B2 | Modular membrane system and method for olefin separation | UOP LLC | 2019-10-01 | — | — | US | disclosed |
| US-20190193021-A1 | MODULAR MEMBRANE SYSTEM AND METHOD FOR OLEFIN SEPARATION | UOP LLC | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10427997-B2 | Modular membrane system and method for olefin separation | SAMM50, PORCN, EMC2 | LMNA 1645/4885TDP1 3753/4885ALDH1A1 3957/4885 |
| US-20190193021-A1 | MODULAR MEMBRANE SYSTEM AND METHOD FOR OLEFIN SEPARATION | SAMM50, PORCN, EMC2 | LMNA 1645/4885TDP1 3753/4885ALDH1A1 3957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.